<DOC>
	<DOCNO>NCT01688232</DOCNO>
	<brief_summary>Medical Scientific Background : Colorectal cancer ( CRC ) lead cancer gender . This cancer prognostic severity . The prognosis cancer significantly improve . The treatment colonic cancer primarily base surgery . Adjuvant chemotherapy propose metastatic cancer ( stage III IV ) . However nearly 30 % patient localized cancer ( stage II ) present recurrence . Despite intense research effort , marker sufficient prognostic value ( independent TNM ) available identify group patient justify intensified therapy . The natural history cancer involve interaction tumor immune system host . The immune infiltration tumor site may indicative host response . We show density intratumor memory T cell ( CD45RO ) cytotoxic T cell ( CD8 ) tumor region ( core invasive margin ) influence occurrence early event metastasis ( tumor embolus ) strongly associate prognosis patient CRC ( Pagès et al , NEJM-2005 ) . This immune criterion well predictor survival `` gold standard '' histoprognostic data tumor invasion ( T stage N ) allow identify group patient high risk recurrence ( *2 ) . The availability immune criterion clinical practice could improve prognostic assessment patient well guide therapeutic . A dedicated platform implement hospital speed transfer immune investigation clinic . The investigation take account density immune cell population tumor region ( core invasive front tumor ) . This methodology validate marker CD45RO , CD3 CD8 lead creation immune score ( `` immunoscore '' range IO I4 ) . We validate prognostic impact immunoscore retrospective series 250 colorectal cancer . The main objective multicentric prospective clinical study assess clinical practice `` immunoscore '' measure prognostic value . The cohort study include 400 patient CRC stage I IV ( 6 center inclusion ; Paris-HEGP , Dijon , Bobigny-Avicenne , Besancon , Poitiers , Rouen ) . Two year inclusion follow-up 3 year patient perform ( co-financing data collection 4th 5th year plan ) . For patient , pathologist center send immunomonitoring platform HEGP tissue section paraffin block contain tumor region . The investigation combine step immunostaining CD3 , CD8 , CD45RO ( Ventana automate ) marker , high-resolution scanning stain slide quantification digital image image module develop group program Developer XD Définiens company . The immunoscore calculate score correlated clinical data relapse survival . The secondary objective program evaluate prognostic performance immune infiltrate biopsy perform diagnostic purpose . This study conduct patient cohort whose biopsy perform hospital surgery whose sample available pathology laboratory involve ( represent 50 % case ) . For patient conduct genetic investigation tumor ass MSI status , presence K-Ras BRAF mutation . This investigation perform tumor section tumor block select immunohistochemical analysis . The section process Department Biology , Hôpital Européen Georges Pompidou . The prognostic performance immune investigation perform tumor section biopsy compare genetic feature tumor . Finally , questionnaire send every six month along monitor patient obtain information concern ( ) emergence immune disorder ( allergy , autoimmunity , inflammatory process ) ( ii ) psychological status patient . The potential impact parameter course disease prediction relapse survival obtain immunoscore performed time surgery evaluate . Expected result : This prospective study indispensable step clinical validation prognostic value immunoscore . The secondary objective help precise benefit concomitant analysis biopsy , genetic feature tumor . The questionnaire help identify clinical parameter track along monitoring</brief_summary>
	<brief_title>The Immunoscore Prognostic Marker Patients With Colorectal Cancer</brief_title>
	<detailed_description>The main objective ass impact immunoscore clinical practice . To end , immune parameter ( CD3 , CD8 , CD45RO ) colorectal cancer ( stage I-IV ) evaluate prospectively large multicenter study . 400 patient CRC stage I IV include ( 6 center inclusion ; Paris-HEGP , Dijon , Bobigny-Avicenne , Besancon , Poitiers , Rouen ) . The number patient include calculated basis inclusion period 24 month , follow-up 3 year ( collection data 4th 5th year plan co-financing ) , expect event rate 20 % , prognostic value immune parameter similar observe retrospective study 399 patient CRC ( *1 ) power test 90 % . During initial management follow-up , therapeutic procedure register ( surgery , radiotherapy , chemotherapy… ) . Data collect clinical examination , radiological exam biological test usually perform hospitalization colorectal cancer : Full clinical examination question presence personal family history CRC , adenoma cancer ; Abdominal ultrasound , chest X-ray ; Computed tomography ( CT ) magnetic resonance imaging ( MRI ) accord clinician 's requirement ; Standard laboratory test blood assay carcinoembryonic antigen ( CEA ) ; The Histopathologic study tumor contain status surgical excision margin , histological type cancer , level parietal invasion , number lymph node examine number metastatic lymph node , accord TNM classification . Patients followed-up every 3 month first 2 year , every 6 month rest follow-up period , recommend . Each patient follow 5 year . Clinical , biological radiological data register specific CRF . Verification inclusion monitor data conduct HEGP Clinical Research Unit ( URC HEGP ) principal investigator . A plan data-management built line monitoring . A questionnaire also send patient every six month five year . This questionnaire build Pr F Pagès psychologists psychiatrist search information concerning ( ) presence immune disorder ( allergy , autoimmunity , inflammatory process ) ( ii ) psychological status patient ( eg . depression ) . After monitoring , data store use double data entry system MS-Access database design URC-HEGP TME.dB database create team principal investigator . The 2 database merge , final data base frozen statistical analysis . Sample preparation : The pathologist center choose tumor block contain core tumor invasive margin . This tumor block part tumor sample routinely process department Pathology diagnosis . three tissue section 4-microns make deposit glass slide perform immunohistochemistry . Four tissue section 4-microns make deposit Eppendorf safe lock tube perform genetic analysis . Anonymous patient name slide tube provide use code number initial patient . If biopsy diagnostic purpose available ( i.e . perform patient initial hospitalization ( 50 % case ) , A tissue section biopsy do . All slide tube sent mail HEGP platform analysis immune infiltrate Biology department genetic analysis . The immunoscore determine use follow step : Immunostainings CD3 , CD8 , CD45RO Benchmark XT automate ; Scanning immunostainings Hamamatsu scanner : Quantification immune population specific tumor area ( core invasive margin ) dedicate image analysis module base recognition histological structure adapt colorectal cancer . This module develop group connection Definiens company . A semi-automatic procedure allow quantification stain cell tumor region . Each region divide tile 800 micron side ( 500 700 tile analyze per tumor ) . The density marker calculate use mean density three tile infiltrate tumor region . A categorization high density ( Hi ) low ( Lo ) marker tumor region interest perform . This categorization do compare observed density optimal cut-off density ( min p value approach ) previously determine DFS OS retrospective study 250 CRC . Genetic analysis : The tube contain section genetic analysis patient inform consent sign genetic investigation transfer Department Biology , Hôpital Européen Georges Pompidou . The % tumor cell specimen determine pathologist ( base H &amp; E evaluation ; le 10 % , 10-20 % , 20-50 % , 50 % tumor cell ) DNA extraction perform . Genetic investigation comprise MSI status , presence K-Ras BRAF mutation</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Adult patient newly diagnose colorectal cancer . Patient sign informed consent . Follow make clinical center inclusion medical team relation center .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>colorectal cancer</keyword>
	<keyword>tumor resection</keyword>
	<keyword>immunoscore</keyword>
	<keyword>lymphocytic density</keyword>
	<keyword>CD3</keyword>
	<keyword>CD8</keyword>
	<keyword>CD45RO</keyword>
	<keyword>biopsy</keyword>
	<keyword>genetic feature tumor</keyword>
	<keyword>relapse</keyword>
	<keyword>immunohistochemistry</keyword>
	<keyword>image analysis software</keyword>
</DOC>